Glycosylation of Recombinant Antibody Therapeutics

The adaptive immune system has the capacity to produce antibodies with a virtually infinite repertoire of specificities. Recombinant antibodies specific for human targets are established in the clinic as therapeutics and represent a major new class of drug. Therapeutic efficacy depends on the formation of complexes with target molecules and subsequent activation of downstream biologic effector mechanisms that result in elimination of the target. The activation of effector mechanisms is dependent on structural characteristics of the antibody molecule that result from posttranslational modifications, in particular, glycosylation. The production of therapeutic antibody with a consistent human glycoform profile has been and remains a considerable challenge to the biopharmaceutical industry. Recent research has shown that individual glycoforms of antibody may provide optimal efficacy for selected outcomes. Thus a further challenge will be the production of a second generation of antibody therapeutics customized for their clinical indication.

[1]  D. Cooper,et al.  Gal alpha 1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus. , 2004, Xenotransplantation.

[2]  R. Jefferis.  The glycosylation of antibody molecules: functional significance. , 1993, Glycoconjugate journal.

[3]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[4]  R. Jefferis,et al.  Interaction sites on human IgG-Fc for FcγR: current models , 2002 .

[5]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.

[6]  U Marx,et al.  Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding. , 1999, The Biochemical journal.

[7]  Kouhei Tsumoto,et al.  Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. , 2004, Journal of molecular biology.

[8]  R. Jefferis,et al.  Expression and characterization of truncated forms of humanized L243 IgG1 , 2000 .

[9]  R. Jefferis,et al.  IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation , 1998, Immunological reviews.

[10]  Robert Huber,et al.  The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex , 2000, Nature.

[11]  R. Jefferis,et al.  Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. , 1996, Journal of immunology.

[12]  J. Davies,et al.  Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. , 2001, Biotechnology and bioengineering.

[13]  M. Aebi,et al.  Degradation of Misfolded Endoplasmic Reticulum Glycoproteins in Saccharomyces cerevisiae Is Determined by a Specific Oligosaccharide Structure , 1998, The Journal of cell biology.

[14]  R. Dwek,et al.  Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.

[15]  J. Deisenhofer.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[16]  M. Du,et al.  Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa‐associated lymphoid tissue lymphoma , 2003, British journal of haematology.

[17]  S. Morrison,et al.  V Region Carbohydrate and Antibody Expression1 , 2004, The Journal of Immunology.

[18]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[19]  U. Galili,et al.  The α-Gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation. , 2001, Biochimie.

[20]  Leonard G. Presta,et al.  Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc , 2000, The Journal of Immunology.

[21]  G J Kleywegt,et al.  Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. , 1995, Structure.

[22]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[23]  H. Nakagawa,et al.  Three-dimensional elution mapping of pyridylaminated N-linked neutral and sialyl oligosaccharides. , 1995, Analytical biochemistry.

[24]  R. Salter,et al.  Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. , 1999, Journal of immunology.

[25]  Y. Fujimura,et al.  Antigen Binding of an Ovomucoid-specific Antibody is Affected by a Carbohydrate Chain Located on the Light Chain Variable Region , 2000, Bioscience, biotechnology, and biochemistry.

[26]  Shan-ying Peng,et al.  [The alpha-gal epitope (Gal alpha 1-3 Gal beta 1-4 GlcNAc-R) in xenotransplantation]. , 2003, Sheng li ke xue jin zhan [Progress in physiology].

[27]  R. Dwek,et al.  Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. , 1996, The Biochemical journal.

[28]  L. Boursier,et al.  Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions. , 2000, Molecular immunology.

[29]  S L Morrison,et al.  Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody. , 1999, Journal of immunology.

[30]  Takaaki Kobayashi,et al.  Release of pig leukocytes during pig kidney perfusion and characterization of pig lymphocyte carbohydrate xenoantigens , 2003, Xenotransplantation.

[31]  Pamela J. Bjorkman,et al.  Crystal structure of the complex of rat neonatal Fc receptor with Fc , 1994, Nature.

[32]  Stephen P. Young,et al.  Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding* , 2001, The Journal of Biological Chemistry.

[33]  M Goodall,et al.  The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. , 2000, Molecular immunology.

[34]  D. Scheinberg,et al.  Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. , 1993, Molecular immunology.

[35]  C. Sautès-Fridman,et al.  The Structure of a Human Type III Fcγ Receptor in Complex with Fc* , 2001, The Journal of Biological Chemistry.

[36]  S L Morrison,et al.  Glycosylation of the variable region of immunoglobulin G--site specific maturation of the sugar chains. , 1995, Molecular immunology.

[37]  D. Cooper.  Xenoantigens and xenoantibodies , 1998, Xenotransplantation.

[38]  D. Cooper,et al.  Galα1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus , 2004 .

[39]  S. High,et al.  Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones? , 2000, FEBS letters.

[40]  M. Taussig,et al.  Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody—antigen interaction , 1997, Nature Structural Biology.

[41]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[42]  Roy Jefferis,et al.  Glycosylation of human IgG antibodies: Relevance to therapeutic applications , 2002 .